Mind Medicine (MindMed) Inc.DFTXEarnings & Financial Report
Definium Therapeutics, Inc., formerly known as MindMed, is a New York-based biotechnology company that is currently developing clinical and therapeutic applications for psychedelic and, more broadly, psychoplastogenic drugs.
Revenue
$1.3M
Gross Profit
N/A
Operating Profit
$-29.2M
Net Profit
$-29.1M
Gross Margin
N/A
Operating Margin
-2226.1%
Net Margin
-2222.0%
YoY Growth
1498.8%
EPS
$-0.76
Mind Medicine (MindMed) Inc. Q2 FY2023 Financial Summary
Mind Medicine (MindMed) Inc. reported revenue of $1.3M (up 1498.8% YoY) for Q2 FY2023, with a net profit of $-29.1M (down 71.8% YoY) (-2222.0% margin).
Key Financial Metrics
| Total Revenue | $1.3M |
|---|---|
| Net Profit | $-29.1M |
| Gross Margin | N/A |
| Operating Margin | -2226.1% |
| Report Period | Q2 FY2023 |
Mind Medicine (MindMed) Inc. Annual Revenue by Year
Mind Medicine (MindMed) Inc. annual revenue history includes year-by-year totals (for example, 2023 revenue was $4.7M).
| Year | Annual Revenue |
|---|---|
| 2023 | $4.7M |
Mind Medicine (MindMed) Inc. Quarterly Revenue & Net Profit History
Mind Medicine (MindMed) Inc. results over the last 7 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2023 | $906.0K | -16.1% | $-23.9M | -2634.0% |
| Q3 FY2023 | $1.2M | +223.1% | $-17.9M | -1541.1% |
| Q2 FY2023 | $1.3M | +1498.8% | $-29.1M | -2222.0% |
| Q1 FY2023 | $1.3M | +4855.6% | $-24.8M | -1932.6% |
| Q4 FY2022 | $1.1M | — | $-4.9M | -454.0% |
| Q3 FY2022 | $360.0K | +662.5% | $-16.5M | -4579.2% |
| Q1 FY2022 | $-27.0K | — | $-18.5M | 68337.0% |
Income Statement
| Q1 2022 | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | |
|---|---|---|---|---|---|---|---|
| Revenue | $-27000 | $360000 | $1.1M | $1.3M | $1.3M | $1.2M | $906000 |
| YoY Growth | N/A | 662.5% | N/A | 4855.6% | 1498.8% | 223.1% | -16.1% |
Balance Sheet
| Q1 2022 | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | |
|---|---|---|---|---|---|---|---|
| Assets | $149.2M | $180.9M | $170.0M | $155.5M | $142.1M | $141.6M | $124.5M |
| Liabilities | $12.4M | $27.3M | $19.1M | $25.2M | $36.1M | $45.6M | $46.4M |
| Equity | $136.8M | $153.6M | $150.9M | $130.3M | $106.0M | $96.0M | $78.1M |
Cash Flow
| Q1 2022 | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | |
|---|---|---|---|---|---|---|---|
| Operating CF | $-12.9M | $-9.3M | $-12.8M | $-13.3M | $-13.8M | $-16.6M | $-20.6M |